{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:15:54Z","timestamp":1772165754470,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["676207"],"award-info":[{"award-number":["676207"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005189","name":"Estonian Research Competency Council","doi-asserted-by":"publisher","award":["PUT1665"],"award-info":[{"award-number":["PUT1665"]}],"id":[{"id":"10.13039\/501100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Polygenic risk scores (PRS) could potentially improve breast cancer screening recommendations. Before a PRS can be considered for implementation, it needs rigorous evaluation, using performance measures that can inform about its future clinical value.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the prognostic performance of a regression model with a previously developed, prevalence-based PRS and age as predictors for breast cancer incidence in women from the Estonian biobank (EstBB) cohort; to compare it to the performance of a model including age only.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed data on 30,312 women from the EstBB cohort. They entered the cohort between 2002 and 2011, were between 20 and 89\u2009years, without a history of breast cancer, and with full 5-year follow-up by 2015. We examined PRS and other potential risk factors as possible predictors in Cox regression models for breast cancer incidence. With 10-fold cross-validation we estimated 3- and 5-year breast cancer incidence predicted by age alone and by PRS plus age, fitting models on 90% of the data. Calibration, discrimination, and reclassification were calculated on the left-out folds to express prognostic performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 101 (3.33\u2030) and 185 (6.1\u2030) incident breast cancers were observed within 3 and 5\u2009years, respectively. For women in a defined screening age of 50\u201362\u2009years, the ratio of observed vs PRS-age modelled 3-year incidence was 0.86 for women in the 75\u201385% PRS-group, 1.34 for the 85\u201395% PRS-group, and 1.41 for the top 5% PRS-group. For 5-year incidence, this was respectively 0.94, 1.15, and 1.08. Yet the number of breast cancer events was relatively low in each PRS-subgroup. For all women, the model\u2019s AUC was 0.720 (95% CI: 0.675\u20130.765) for 3-year and 0.704 (95% CI: 0.670\u20130.737) for 5-year follow-up, respectively, just 0.022 and 0.023 higher than for the model with age alone. Using a 1% risk prediction threshold, the 3-year NRI for the PRS-age model was 0.09, and 0.05 for 5\u2009years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The model including PRS had modest incremental performance over one based on age only. A larger, independent study is needed to assess whether and how the PRS can meaningfully contribute to age, for developing more efficient screening strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-021-08937-8","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T08:10:52Z","timestamp":1639987852000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluating the prognostic performance of a polygenic risk score for breast cancer risk stratification"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8246-1510","authenticated-orcid":false,"given":"Maria","family":"Olsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krista","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick M.","family":"Bossuyt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Els","family":"Goetghebeur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"key":"8937_CR1","unstructured":"American Cancer Society. Cancer Facts and Figures. Atlanta Am Cancer Soc. 2020:2020."},{"key":"8937_CR2","unstructured":"Recommendations from European Breast Guidelines [Internet]. European Commission initiative on breast cancer. Available from: https:\/\/ecibc.jrc.ec.europa.eu\/recommendations\/. Accessed 13 Mar 2019."},{"key":"8937_CR3","first-page":"1","volume":"124","author":"HD Nelson","year":"2016","unstructured":"Nelson HD, Cantor A, Humphrey L, Fu R, Pappas M, Daeges M, et al. Screening for breast Cancer: a systematic review to update the 2009 U.S. preventive services task force recommendation. Evid Synth. 2016;124:1\u2013277.","journal-title":"Evid Synth"},{"key":"8937_CR4","unstructured":"The National Health Service (NHS). Breast cancer screening [Internet]. Available from: https:\/\/www.nhs.uk\/conditions\/breast-cancer-screening\/. Accessed 16 May 2020"},{"issue":"9855","key":"8937_CR5","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/S0140-6736(12)61611-0","volume":"380","author":"M Marmot","year":"2012","unstructured":"Marmot M, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380(9855):1778\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(12)61611-0.","journal-title":"Lancet"},{"key":"8937_CR6","unstructured":"Cancer Research UK. Breast cancer incidence (invasive) statistics [Internet]. Available from: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/breast-cancer\/incidence-invasive#heading-One. Accessed Jul 9 2020."},{"key":"8937_CR7","unstructured":"Integraal kankercentrum Nederland (KNL). NKR Cijfers [Internet]. Available from: https:\/\/iknl.nl\/. Accessed 9 Jul 2020."},{"key":"8937_CR8","doi-asserted-by":"crossref","unstructured":"G\u00f8tzsche PC, J\u00f8rgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013;(6):CD001877.","DOI":"10.1002\/14651858.CD001877.pub5"},{"issue":"1_suppl","key":"8937_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1258\/jms.2012.012083","volume":"19","author":"S Hofvind","year":"2012","unstructured":"Hofvind S, Ponti A, Patnick J, Ascunce N, Njor S, Broeders M, et al. False-positive results in mammographic screening for breast cancer in Europe: a literature review and survey of service screening programmes. J Med Screen. 2012;19(1_suppl):57\u201366. https:\/\/doi.org\/10.1258\/jms.2012.012083.","journal-title":"J Med Screen"},{"issue":"suppl 5","key":"8937_CR10","doi-asserted-by":"publisher","first-page":"v103","DOI":"10.1093\/annonc\/mdw327","volume":"27","author":"S Paluch-Shimon","year":"2016","unstructured":"Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F, et al. Prevention and screening in BRCA mutation carriers and other breast\/ovarian hereditary cancer syndromes: ESMO clinical practice guidelines for cancer prevention and screening. Ann Oncol. 2016;27(suppl 5):v103\u201310. https:\/\/doi.org\/10.1093\/annonc\/mdw327.","journal-title":"Ann Oncol"},{"key":"8937_CR11","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.7150\/ijbs.21635","volume":"13","author":"YS Sun","year":"2017","unstructured":"Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, et al. Risk factors and preventions of breast cancer. Int J Biol Sci. 2017;13:1387\u201397.","journal-title":"Int J Biol Sci"},{"key":"8937_CR12","first-page":"1301","volume":"83","author":"Anglian Breast Cancer Study Group","year":"2002","unstructured":"Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer. 2002;83:1301\u20138.","journal-title":"Br J Cancer"},{"issue":"12","key":"8937_CR13","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jama.279.12.915","volume":"279","author":"B Newman","year":"1998","unstructured":"Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. J Am Med Assoc. 1998;279(12):915\u201321. https:\/\/doi.org\/10.1001\/jama.279.12.915.","journal-title":"J Am Med Assoc"},{"issue":"9","key":"8937_CR14","doi-asserted-by":"publisher","first-page":"19581","DOI":"10.1038\/s41576-018-0018-x","volume":"19","author":"A Torkamani","year":"2018","unstructured":"Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. Nat Rev Genet. 2018;19(9):19581\u201390. https:\/\/doi.org\/10.1038\/s41576-018-0018-x.","journal-title":"Nat Rev Genet"},{"issue":"7","key":"8937_CR15","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nrg.2016.27","volume":"17","author":"N Chatterjee","year":"2016","unstructured":"Chatterjee N, Shi J, Garc\u00eda-Closas M. Developing and evaluating polygenic risk prediction models for stratified disease prevention. Nat Rev Genet. 2016;17(7):392\u2013406. https:\/\/doi.org\/10.1038\/nrg.2016.27.","journal-title":"Nat Rev Genet"},{"issue":"1","key":"8937_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms9559","volume":"6","author":"B Kinnersley","year":"2015","unstructured":"Kinnersley B, Labussi\u00e8re M, Holroyd A, Di Stefano AL, Broderick P, Vijayakrishnan J, et al. Genome-wide association study identifies multiple susceptibility loci for glioma. Nat Commun. 2015;6(1):1\u20139. https:\/\/doi.org\/10.1038\/ncomms9559.","journal-title":"Nat Commun"},{"issue":"8","key":"8937_CR17","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/ng2089","volume":"39","author":"BW Zanke","year":"2007","unstructured":"Zanke BW, Greenwood CMT, Rangrej J, Kustra R, Tenesa A, Farrington SM, et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet. 2007;39(8):989\u201394. https:\/\/doi.org\/10.1038\/ng2089.","journal-title":"Nat Genet"},{"issue":"5","key":"8937_CR18","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/ng2022","volume":"39","author":"M Yeager","year":"2007","unstructured":"Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet. 2007;39(5):645\u20139. https:\/\/doi.org\/10.1038\/ng2022.","journal-title":"Nat Genet"},{"issue":"1","key":"8937_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ajhg.2018.11.002","volume":"104","author":"N Mavaddat","year":"2019","unstructured":"Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, et al. Polygenic risk scores for prediction of breast Cancer and breast Cancer subtypes. Am J Hum Genet. 2019;104(1):21\u201334. https:\/\/doi.org\/10.1016\/j.ajhg.2018.11.002.","journal-title":"Am J Hum Genet"},{"issue":"11","key":"8937_CR20","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1056\/NEJMoa0907727","volume":"362","author":"S Wacholder","year":"2010","unstructured":"Wacholder S, Hartge P, Prentice R, Garcia-Closas M, Feigelson HS, Diver WR, et al. Performance of common genetic variants in breast-cancer risk models. N Engl J Med. 2010;362(11):986\u201393. https:\/\/doi.org\/10.1056\/NEJMoa0907727.","journal-title":"N Engl J Med"},{"key":"8937_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/jnci\/djv036","volume":"107","author":"N Mavaddat","year":"2015","unstructured":"Mavaddat N, PDP P, Michailidou K, Tyrer J, Brook MN, Bolla MK, et al. Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. J Natl Cancer Inst. 2015;107:36.","journal-title":"J Natl Cancer Inst"},{"key":"8937_CR22","doi-asserted-by":"publisher","unstructured":"Deng N, Zhou H, Fan H, Yuan Y. Single nucleotide polymorphisms and cancer susceptibility. 2017;8(66):110635\u201349. https:\/\/doi.org\/10.18632\/oncotarget.22372.","DOI":"10.18632\/oncotarget.22372"},{"issue":"9","key":"8937_CR23","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/aje\/kwh101","volume":"159","author":"MS Pepe","year":"2004","unstructured":"Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol. 2004;159(9):882\u201390. https:\/\/doi.org\/10.1093\/aje\/kwh101.","journal-title":"Am J Epidemiol"},{"issue":"25","key":"8937_CR24","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1056\/NEJMp068249","volume":"355","author":"JH Ware","year":"2006","unstructured":"Ware JH. The limitations of risk factors as prognostic tools. N Engl J Med. 2006;355(25):2615\u20137. https:\/\/doi.org\/10.1056\/NEJMp068249.","journal-title":"N Engl J Med"},{"issue":"7224","key":"8937_CR25","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1136\/bmj.319.7224.1562","volume":"319","author":"NJ Wald","year":"1999","unstructured":"Wald NJ, Hackshaw AK, Frost CD. When can a risk factor be used as a worthwhile screening test? BMJ. 1999;319(7224):1562\u20135. https:\/\/doi.org\/10.1136\/bmj.319.7224.1562.","journal-title":"BMJ"},{"issue":"10","key":"8937_CR26","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1001\/jamaoncol.2016.1025","volume":"2","author":"P Maas","year":"2016","unstructured":"Maas P, Barrdahl M, Joshi AD, Auer PL, Gaudet MM, Milne RL, et al. Breast Cancer risk from modifiable and nonmodifiable risk factors among white women in the United States. JAMA Oncol. 2016;2(10):1295\u2013302. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1025.","journal-title":"JAMA Oncol"},{"issue":"1","key":"8937_CR27","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1186\/s12885-019-5783-1","volume":"19","author":"K L\u00e4ll","year":"2019","unstructured":"L\u00e4ll K, Lepamets M, Palover M, Esko T, Metspalu A, T\u00f5nisson N, et al. Polygenic prediction of breast cancer: comparison of genetic predictors and implications for risk stratification. BMC Cancer. 2019;19(1):557. https:\/\/doi.org\/10.1186\/s12885-019-5783-1.","journal-title":"BMC Cancer"},{"issue":"1","key":"8937_CR28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/EDE.0b013e3181c30fb2","volume":"21","author":"EW Steyerberg","year":"2010","unstructured":"Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21(1):128\u201338. https:\/\/doi.org\/10.1097\/EDE.0b013e3181c30fb2.","journal-title":"Epidemiology"},{"issue":"4","key":"8937_CR29","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1093\/ije\/dyt268","volume":"44","author":"L Leitsalu","year":"2015","unstructured":"Leitsalu L, Haller T, Esko T, Tammesoo M-L, Alavere H, Snieder H, et al. Cohort profile: Estonian biobank of the Estonian genome center. Univ Tartu Int J Epidemiol. 2015;44(4):1137\u201347. https:\/\/doi.org\/10.1093\/ije\/dyt268.","journal-title":"Univ Tartu Int J Epidemiol"},{"key":"8937_CR30","unstructured":"Estonian Genome Center 2001 - 2011. University of Tartu.[Internet]. Available from: https:\/\/genomics.ut.ee\/sites\/default\/files\/geenivaramu\/estoniangenomecenter.pdf. Accessed 18 Oct 2019."},{"key":"8937_CR31","unstructured":"University of Tartu Institute of Genomics [Internet]. Available from: https:\/\/www.geenivaramu.ee\/en\/about-us. Accessed 9 Jul 2019"},{"issue":"2","key":"8937_CR32","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/joim.12320","volume":"277","author":"L Milani","year":"2015","unstructured":"Milani L, Leitsalu L, Metspalu A. An epidemiological perspective of personalized medicine: the Estonian experience. J Intern Med. 2015;277(2):188\u2013200. https:\/\/doi.org\/10.1111\/joim.12320.","journal-title":"J Intern Med"},{"issue":"2","key":"8937_CR33","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/03630242.2015.1086468","volume":"56","author":"K Innos","year":"2016","unstructured":"Innos K, Valvere V, Padrik P, Eelma E, K\u00fctner R, Lehtsaar J, et al. Mammography use and mode of detection among breast cancer patients in Estonia. Women Heal. 2016;56(2):129\u201340. https:\/\/doi.org\/10.1080\/03630242.2015.1086468.","journal-title":"Women Heal"},{"issue":"2","key":"8937_CR34","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/sim.2929","volume":"27","author":"MJ Pencina","year":"2008","unstructured":"Pencina MJ, D\u2019Agostino RB, D\u2019Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157\u201372. https:\/\/doi.org\/10.1002\/sim.2929.","journal-title":"Stat Med"},{"issue":"3","key":"8937_CR35","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/gim.2016.103","volume":"19","author":"K L\u00e4ll","year":"2017","unstructured":"L\u00e4ll K, M\u00e4gi R, Morris A, Metspalu A, Fischer K. Personalized risk prediction for type 2 diabetes: the potential of genetic risk scores. Genet Med. 2017;19(3):322\u20139. https:\/\/doi.org\/10.1038\/gim.2016.103.","journal-title":"Genet Med"},{"issue":"9","key":"8937_CR36","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1136\/jmedgenet-2011-100716","volume":"49","author":"A H\u00fcsing","year":"2012","unstructured":"H\u00fcsing A, Canzian F, Beckmann L, Garcia-Closas M, Diver WR, Thun MJ, et al. Prediction of breast cancer risk by genetic risk factors, overall and by hormone receptor status. J Med Genet. 2012;49(9):601\u20138. https:\/\/doi.org\/10.1136\/jmedgenet-2011-100716.","journal-title":"J Med Genet"},{"key":"8937_CR37","doi-asserted-by":"publisher","unstructured":"Shieh Y, Hu D, Ma L, Huntsman S, Gard CC, Leung JWT, et al. Breast cancer risk prediction using a clinical risk model and polygenic risk score. Breast Cancer Res Treat. 2016;159(3):513\u201325. https:\/\/doi.org\/10.1007\/s10549-016-3953-2.","DOI":"10.1007\/s10549-016-3953-2"},{"issue":"21","key":"8937_CR38","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1093\/jnci\/djq388","volume":"102","author":"ME Mealiffe","year":"2010","unstructured":"Mealiffe ME, Stokowski RP, Rhees BK, Prentice RL, Pettinger M, Hinds DA. Assessment of clinical validity of a breast Cancer risk model combining genetic and clinical information. J Natl Cancer Inst. 2010;102(21):1618\u201327. https:\/\/doi.org\/10.1093\/jnci\/djq388.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"8937_CR39","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/jnci\/dju397","volume":"107","author":"CM Vachon","year":"2015","unstructured":"Vachon CM, Pankratz VS, Scott CG, Haeberle L, Ziv E, Jensen MR, et al. The contributions of breast density and common genetic variation to breast Cancer risk. J Natl Cancer Inst. 2015;107(5):397. https:\/\/doi.org\/10.1093\/jnci\/dju397.","journal-title":"J Natl Cancer Inst."},{"issue":"1","key":"8937_CR40","doi-asserted-by":"publisher","first-page":"R25","DOI":"10.1186\/bcr3110","volume":"14","author":"H Darabi","year":"2012","unstructured":"Darabi H, Czene K, Zhao W, Liu J, Hall P, Humphreys K. Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement. Breast Cancer Res. 2012;14(1):R25. https:\/\/doi.org\/10.1186\/bcr3110.","journal-title":"Breast Cancer Res"},{"key":"8937_CR41","unstructured":"International Agency for Research on Cancer, WHO. Globocan 2018. Estonia. [Internet]. Available from: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/233-estonia-fact-sheets.pdf. Accessed 13 Mar 2019."},{"issue":"9","key":"8937_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002644","volume":"15","author":"X Zhang","year":"2018","unstructured":"Zhang X, Rice M, Tworoger SS, Rosner BA, Eliassen AH, Tamimi RM, et al. Addition of a polygenic risk score, mammographic density, and endogenous hormones to existing breast cancer risk prediction models: a nested case\u2013control study. PLoS Med. 2018;15(9):e1002644. https:\/\/doi.org\/10.1371\/journal.pmed.1002644.","journal-title":"PLoS Med"},{"key":"8937_CR43","unstructured":"Estonian Genome Centre. University of Tartu Institute of Genomics [Internet]. Available from: https:\/\/genomics.ut.ee\/en\/about-us\/estonian-genome-centre. Accessed 20 Oct 2020"},{"key":"8937_CR44","unstructured":"BBMRI.ee: Estonian Biobank has now recruited over 200,000 biobank participants and all will be genotyped by June 2020. University of Tartu Institute of Genomics [Internet]. Available from: https:\/\/genomics.ut.ee\/en\/news. Accessed on 20 Oct 2020"},{"key":"8937_CR45","unstructured":"Estonia Houses The Biggest Biobank In Europe [Internet]. Available from: https:\/\/www.forbes.com\/sites\/yiannismouratidis\/2019\/01\/30\/estonia-houses-the-biggest-biobank-in-europe\/#187a6658227a. Accessed 20 Oct 2020"},{"key":"8937_CR46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cca.2013.09.018","volume":"427","author":"AR Horvath","year":"2014","unstructured":"Horvath AR, Lord SJ, StJohn A, Sandberg S, Cobbaert CM, Lorenz S, et al. From biomarkers to medical tests: the changing landscape of test evaluation. Clin Chim Acta. 2014;427:49\u201357. https:\/\/doi.org\/10.1016\/j.cca.2013.09.018.","journal-title":"Clin Chim Acta"},{"issue":"1","key":"8937_CR47","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41523-017-0035-5","volume":"3","author":"LJ Esserman","year":"2017","unstructured":"Esserman LJ. The WISDOM Study: breaking the deadlock in the breast cancer screening debate. Npj Breast Cancer. 2017;3(1):34. https:\/\/doi.org\/10.1038\/s41523-017-0035-5.","journal-title":"Npj Breast Cancer"},{"key":"8937_CR48","unstructured":"Home Page - MyPeBS [Internet]. Available from: https:\/\/mypebs.eu\/. Accessed 9 Jul 2020"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08937-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08937-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08937-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T08:13:50Z","timestamp":1639988030000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08937-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8937"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08937-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-121122\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"5 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants have given informed consent and the current analysis falls under the ethics approval for the study of L\u00e4ll and colleauges, granted by the Research Ethics Committee of the University of Tartu (approval 234\/T-12) [\n                      \n                      ]. EstBB: All human research was approved by the Research Ethics Committee of the University of Tartu (approval 234\/T-12), and conducted according to the Declaration of Helsinki. All participants provided written informed consent to participate in the Estonian Biobank.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1351"}}